Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dermatophagoides species, primarily Dermatophagoides pteronyssinus and Dermatophagoides farinae, are microscopic mites that serve as the most prevalent source of indoor aeroallergens worldwide [7, 8]. These organisms produce over 30 distinct groups of allergenic proteins found in their digestive tracts and fecal pellets, with Group 1 (cysteine proteases) and Group 2 (lipid-binding proteins) being the primary drivers of sensitization [6, 11]. Inhalation or skin contact with these allergens triggers an IgE-mediated Type I hypersensitivity reaction, leading to chronic inflammatory conditions such as allergic rhinitis, bronchial asthma, and atopic dermatitis [1, 10]. In the pharmaceutical industry, Dermatophagoides species are used as the source material for allergen-specific immunotherapy (AIT) products, including sublingual tablets and subcutaneous injections [4, 13]. These treatments aim to modify the underlying disease by inducing immunological tolerance, shifting the immune profile from a pro-allergic Th2 state toward a regulatory or Th1-weighted response [2, 5].
Allergen-specific immunotherapy (AIT) involves the repeated administration of Dermatophagoides extracts to induce peripheral T-cell tolerance, stimulate the production of regulatory T cells (Tregs), and promote a class switch to allergen-specific IgG4 antibodies that block IgE-mediated mast cell activation [1, 5].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House dust mite (Dermatophagoides species) (HDM).